Allergy Relief Multisymptom
NDC 52904-457
Product Information
Allergy Relief Multisymptom is a OTC MONOGRAPH FINAL-approved product labeled by Select Corporation. This product is primarily utilized in pharmaceutical processing or compounding. It is supplied as a white product. This product entry covers the primary NDC 52904-457 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
FR11
Code Structure Chart
Product Details
What is NDC 52904-457?
What are the uses of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- ACETAMINOPHEN (UNII: 362O9ITL9D)
- ACETAMINOPHEN (UNII: 362O9ITL9D) (Active Moiety)
- CHLORPHENIRAMINE MALEATE (UNII: V1Q0O9OJ9Z)
- CHLORPHENIRAMINE (UNII: 3U6IO1965U) (Active Moiety)
- PHENYLEPHRINE HYDROCHLORIDE (UNII: 04JA59TNSJ)
- PHENYLEPHRINE (UNII: 1WS297W6MV) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- POVIDONE K29/32 (UNII: 390RMW2PEQ)
- SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2)
- CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)
- STEARIC ACID (UNII: 4ELV7Z65AP)
- MALTODEXTRIN (UNII: 7CVR7L4A2D)
- STARCH, CORN (UNII: O8232NY3SJ)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 1046781 - acetaminophen 325 MG / chlorpheniramine maleate 2 MG / phenylephrine HCl 5 MG Oral Tablet
- RxCUI: 1046781 - acetaminophen 325 MG / chlorpheniramine maleate 2 MG / phenylephrine hydrochloride 5 MG Oral Tablet
- RxCUI: 1046781 - APAP 325 MG / chlorpheniramine maleate 2 MG / phenylephrine hydrochloride 5 MG Oral Tablet
* Please review the full disclaimer at the bottom of this page.